Table 1.
Analyses of tumour-infiltrating CD68+ and CD163+ macrophages in the breast tumours in women with LLABCs and subsequent PCR following NAC.
| Macrophages | Groups | Pre-NAC | |||
|---|---|---|---|---|---|
| Low infiltration (n) | High infiltration (n) | Pearson chi-square value (GPR versus PPR, PCR versus non-PCR) | p value | ||
| CD68+ (n = 16) | Good pathological response (GPR, n = 9) | 5 | 4 | 1.667 | 0.197 |
| Poor pathological response (PPR, n = 7) | 6 | 1 | |||
| Pathological complete response (PCR, n = 6) | 3 | 3 | 1.571 | 0.210 | |
| Nonpathological complete response (non-PCR, n = 10) | 8 | 2 | |||
|
| |||||
| CD163+ (n = 33) | Good pathological response (GPR, n = 21) | 5 | 16 | 8.192 | 0.004∗ |
| Poor pathological response (PPR, n = 12) | 9 | 3 | |||
| Pathological complete response (PCR, n = 16) | 3 | 13 | 7.127 | 0.008∗ | |
| Nonpathological complete response (non-PCR, n = 17) | 11 | 6 | |||
LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; ∗statistically significant.